Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Role of Mitochondria in Non Severe Asthma

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nuoroda įrašoma į mainų sritį
StatusasBaigta
Rėmėjai
University Hospital, Bordeaux

Raktažodžiai

Santrauka

Asthma is a frequent disease characterized by bronchial hyperresponsiveness, inflammation and remodelling. Bronchial remodelling is an abnormal repair process that contributes to the development of poorly reversible airway narrowing. It can appear very early in the evolution of the disease and involves an increased mass of bronchial smooth muscle (BSM). The mechanism of such an increase has been related with an increase in smooth muscle cell proliferation. Recently, we have demonstrated that, BSM increased proliferation is induced by an enhanced mitochondrial biogenesis in severe asthma (T. Trian et al. J Exp Med 2007). The objective of this study is to investigate the role of smooth muscle cell mitochondria in non severe asthma

apibūdinimas

Bronchial remodelling mainly involves an increased mass of bronchial smooth muscle (BSM), which is related with an increase proliferation of BSM cells. Recently, using BSM cells obtained from severe asthmatics, we have demonstrated that such an increase proliferation was induced by an activation cascade involving an abnormal calcium entry, and the subsequent activation of Calmodulin-kinase IV, PGC-1alpha, NRF-1 and mt-TFA leading to an increase mitochondrial biogenesis (T. Trian et al, J Exp Med 2007). The objective of this study is to investigate the role of BSM cell mitochondria in non severe asthma.

For this purpose, 30 non severe asthmatic adult patients (>18 yr) will be prospectively recruited from the "CHU de Bordeaux" according to the Global Initiative for Asthma (GINA) guidelines. Inclusion visit will include written informed consent, asthma control questionnaire, clinical examination, lung function testing (i.e. arterial gas, exhaled NO, plethysmography), prick tests, chest X Ray and blood sample for total IgE levels. Bronchial specimens will be obtained from all subjects by fiberoptic bronchoscopy. BSM remodelling will be evaluated by morphological analysis. Patients will be divided into 2 groups according to the presence or the absence of BSM remodelling. Using BSM cell culture, the role of mitochondria will be analyzed by electronic microscopy, confocal microscopy, immunoblotting, RT-PCR and oxygraphy.

Datos

Paskutinį kartą patikrinta: 01/31/2010
Pirmasis pateikimas: 12/14/2008
Numatytas registravimas pateiktas: 12/14/2008
Pirmas paskelbtas: 12/15/2008
Paskutinis atnaujinimas pateiktas: 02/14/2010
Paskutinis atnaujinimas paskelbtas: 02/16/2010
Faktinė studijų pradžios data: 01/31/2009
Numatoma pirminio užbaigimo data: 10/31/2009
Numatoma studijų užbaigimo data: 10/31/2009

Būklė ar liga

Asthma

Intervencija / gydymas

Procedure: 1

Fazė

-

Rankų grupės

RankaIntervencija / gydymas
Experimental: 1
fiberoptic fibroscopy
Procedure: 1
Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment

Tinkamumo kriterijai

Amžius, tinkami studijuoti 18 Years Į 18 Years
Tinkamos studijoms lytysAll
Priima sveikus savanoriusTaip
Kriterijai

Inclusion Criteria:

- Male or female aged more than 18 years

- Diagnosis of intermittent asthma, mild persistent asthma or moderate persistent according to ATS criteria

- Forced expiratory volume in one second > 60% predicted

- Written informed consent

Exclusion Criteria:

- Smoker or former smoker (tobacco or cannabis)

- Adults protected by law

- Subjects not affiliated with social security

- Subjects during exclusion relative to another protocol or for which the annual maximum allowance of 3800 euros has been reached

- Subject with any co-morbidity (except chronic rhinitis, chronic sinusitis nasal polyps or gastro-oesophageal reflux)

- Asthma exacerbation within 6 weeks before enrolment

- Infections of the upper airway within 3 months before enrolment

- Chronic viral infections (hepatitis, HIV)

- Pregnancy or breastfeeding

- Contraindications to bronchoscopy

Rezultatas

Pirminės rezultatų priemonės

1. BSM mitochondrial biogenesis assessed by the number of mitochondrial sections using electron microscopy, the porin content using western blot, and mitochondrial oxygen consumption evaluated by oxygraphy. [One bronchial fiberoptic fibroscopy within 15 days after the enrolment]

Antrinės rezultatų priemonės

1. BSM remodelling assessed by optic microscopy and immunohistochemistry (using anti-alpha smooth muscle actin antibody). [One bronchial fiberoptic fibroscopy within 15 days after the enrolment]

2. Transcription factors involved in mitochondrial biogenesis assessed by quantitative RT-PCR and western blot. [One bronchial fiberoptic fibroscopy within 15 days after the enrolment]

Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge